| Year |
Citation |
Score |
| 2024 |
Yll-Pico M, Park Y, Martinez J, Iniguez A, Kha M, Kim T, Medrano L, Nguyen VH, Kaltcheva T, Dempsey S, Chiuppesi F, Wussow F, Diamond DJ. Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform. Npj Vaccines. 9: 68. PMID 38555379 DOI: 10.1038/s41541-024-00859-3 |
0.354 |
|
| 2023 |
Chiuppesi F, Ortega-Francisco S, Gutierrez MA, Li J, Ly M, Faircloth K, Mack-Onyeike J, La Rosa C, Thomas S, Zhou Q, Drake J, Slape C, Fernando P, Rida W, Kaltcheva T, et al. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy. Vaccines. 11. PMID 37766168 DOI: 10.3390/vaccines11091492 |
0.389 |
|
| 2023 |
La Rosa C, Chiuppesi F, Park Y, Zhou Q, Yang D, Gendzekhadze K, Ly M, Li J, Kaltcheva T, Ortega Francisco S, Gutierrez MA, Ali H, Otoukesh S, Amanam I, Salhotra A, et al. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study. Frontiers in Immunology. 14: 1114131. PMID 36936918 DOI: 10.3389/fimmu.2023.1114131 |
0.35 |
|
| 2023 |
La Rosa C, Aldoss I, Park Y, Yang D, Zhou Q, Gendzekhadze K, Kaltcheva T, Rida W, Dempsey S, Arslan S, Artz A, Ball B, Nikolaenko L, Pullarkat VA, Nakamura R, et al. Hematopoietic stem cell donor vaccination with CMV Triplex augments frequencies of functional and durable CMV-specific T cells in the recipient: a novel strategy to limit antiviral prophylaxis. American Journal of Hematology. PMID 36594185 DOI: 10.1002/ajh.26824 |
0.406 |
|
| 2022 |
Chiuppesi F, Zaia JA, Faircloth K, Johnson D, Ly M, Karpinski V, La Rosa C, Drake J, Marcia J, Acosta AM, Dempsey S, Taplitz RA, Zhou Q, Park Y, Francisco SO, ... Kaltcheva T, et al. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. Iscience. 104745. PMID 35846380 DOI: 10.1016/j.isci.2022.104745 |
0.381 |
|
| 2022 |
Chiuppesi F, Nguyen VH, Park Y, Contreras H, Karpinski V, Faircloth K, Nguyen J, Kha M, Johnson D, Martinez J, Iniguez A, Zhou Q, Kaltcheva T, Frankel P, Kar S, et al. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. Npj Vaccines. 7: 7. PMID 35064109 DOI: 10.1038/s41541-022-00436-6 |
0.333 |
|
| 2022 |
Pourhassan H, LA Rosa C, Chiuppesi F, Puing A, Aldoss I, Park Y, Zhou Q, Karpinski V, Faircloth K, Kaltcheva T, Johnson D, Ortega Francisco S, Zaia JA, Nakamura R, Al Malki MM, et al. Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity. Blood Advances. PMID 35008104 DOI: 10.1182/bloodadvances.2021006282 |
0.3 |
|
| 2021 |
Chiuppesi F, Nguyen VH, Park Y, Contreras H, Karpinski V, Faircloth K, Nguyen J, Kha M, Johnson D, Martinez J, Iniguez A, Zhou Q, Kaltcheva T, Frankel P, Kar S, et al. Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates. Biorxiv : the Preprint Server For Biology. PMID 34545366 DOI: 10.1101/2021.09.15.460487 |
0.333 |
|
| 2020 |
Chiuppesi F, Salazar MD, Contreras H, Nguyen VH, Martinez J, Park Y, Nguyen J, Kha M, Iniguez A, Zhou Q, Kaltcheva T, Levytskyy R, Ebelt ND, Kang TH, Wu X, et al. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nature Communications. 11: 6121. PMID 33257686 DOI: 10.1038/s41467-020-19819-1 |
0.333 |
|
| 2020 |
Chiuppesi F, Salazar MDA, Contreras H, Nguyen V, Martinez J, Park S, Nguyen J, Kha M, Iniguez A, Zhou Q, Kaltcheva T, Levytskyy R, Ebelt N, Kang T, Wu X, et al. Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform. Research Square. PMID 32702732 DOI: 10.21203/rs.3.rs-40198/v1 |
0.337 |
|
| 2020 |
Chiuppesi F, Salazar MD, Contreras H, Nguyen VH, Martinez J, Park S, Nguyen J, Kha M, Iniguez A, Zhou Q, Kaltcheva T, Levytskyy R, Ebelt ND, Kang TH, Wu X, et al. Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine. Biorxiv : the Preprint Server For Biology. PMID 32637957 DOI: 10.1101/2020.07.01.183236 |
0.336 |
|
| 2020 |
Aldoss I, La Rosa C, Baden LR, Longmate J, Ariza-Heredia EJ, Rida WN, Lingaraju CR, Zhou Q, Martinez J, Kaltcheva T, Dagis A, Hardwick N, Issa NC, Farol L, Nademanee A, et al. Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial. Annals of Internal Medicine. PMID 32040960 DOI: 10.7326/M19-2511 |
0.33 |
|
| 2018 |
La Rosa C, Longmate J, Lingaraju CR, Zhou Q, Kaltcheva T, Hardwick N, Aldoss I, Nakamura R, Diamond DJ. Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Non-Viremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30562587 DOI: 10.1016/j.bbmt.2018.12.070 |
0.444 |
|
| 2018 |
Chiuppesi F, Nguyen J, Park S, Contreras H, Kha M, Meng Z, Kaltcheva T, Iniguez A, Martinez J, La Rosa C, Wussow F, Diamond DJ. Multi-Antigenic Modified Vaccinia Ankara Vaccine Vectors to Elicit Potent Humoral and Cellular Immune Reponses Against Human Cytomegalovirus in Mice. Journal of Virology. PMID 30045984 DOI: 10.1128/JVI.01012-18 |
0.361 |
|
| 2016 |
La Rosa C, Longmate J, Martinez J, Zhou Q, Kaltcheva TI, Tsai W, Drake J, Carroll M, Wussow F, Chiuppesi F, Hardwick N, Dadwal S, Aldoss I, Nakamura R, Zaia JA, et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T-cells in healthy adults. Blood. PMID 27760761 DOI: 10.1182/blood-2016-07-729756 |
0.412 |
|
| 2014 |
Hardwick NR, Carroll M, Kaltcheva T, Qian D, Lim D, Leong L, Chu P, Kim J, Chao J, Fakih M, Yen Y, Espenschied J, Ellenhorn JD, Diamond DJ, Chung V. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4459-70. PMID 24987057 DOI: 10.1158/1078-0432.CCR-13-3361 |
0.316 |
|
| 2013 |
Israyelyan A, La Rosa C, Tsai W, Kaltcheva T, Srivastava T, Aquino L, Li J, Kim Y, Palmer J, Streja L, Senitzer D, Zaia JA, Rosenwald A, Forman SJ, Nakamura R, et al. Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma. 54: 2490-9. PMID 23480492 DOI: 10.3109/10428194.2013.783910 |
0.348 |
|
| 2012 |
La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Dadwal S, Kelsey MI, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. The Journal of Infectious Diseases. 205: 1294-304. PMID 22402037 DOI: 10.1093/infdis/jis107 |
0.401 |
|
| 2011 |
Manuel ER, Blache CA, Paquette R, Kaltcheva TI, Ishizaki H, Ellenhorn JD, Hensel M, Metelitsa L, Diamond DJ. Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer Research. 71: 4183-91. PMID 21527558 DOI: 10.1158/0008-5472.CAN-10-4676 |
0.331 |
|
| Show low-probability matches. |